Skip to search formSkip to main contentSkip to account menu

(124)I-cMAb U36

Known as: 124I-cMAb U36 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Monoclonal AntibodiescMAb U36

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Zirconium-89 Labeled Antibodies: A New Tool for Molecular Imaging in Cancer Patients
Antibody based positron emission tomography (immuno-PET) imaging is of increasing importance to visualize and characterize tumor… 
Highly Cited
2009
Highly Cited
2009
Radiation Dosimetry of 89Zr-Labeled Chimeric Monoclonal Antibody U36 as Used for Immuno-PET in Head and Neck Cancer Patients
Immuno-PET is an appealing concept in the detection of tumors and planning of antibody-based therapy. For this purpose, the long… 
2008
2008
Targeting CD44v6 Expressed in Head and Neck Squamous Cell Carcinoma: Preclinical Characterization of an 111In-Labeled Monoclonal Antibody
In patients with head and neck squamous cell carcinoma (HNSCC) radioimmunodiagnosis could offer a more specific and sensitive… 
2006
2006
Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies
PurposeWe tested the suitability of the chimeric monoclonal anti-human CD44 splice version 6 antibody (cMAb U36) for targeting… 
2005
2005
In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma
PurposeThe purpose of this study was to analyse the properties of the astatinated chimeric MAb (cMAb) U36 as a conjugate to… 
Highly Cited
2004
Highly Cited
2004
High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy
PurposeMonoclonal antibodies (MAbs) labelled with 124I are an attractive option for quantitative imaging with positron emission… 
2003
2003
Biodistribution of the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecaborate-containing linker. Comparison with other radioiodination methods.
We have evaluated the applicability of the [(4-isothiocyanatobenzylammonio)undecahydro-closo-dodecaborate (1-)] (DABI) linker… 
2002
2002
Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose…
PURPOSE In an earlier Phase I radioimmunotherapy (RIT) study with rhenium-186-labeled chimeric monoclonal antibody (cMAb) U36 in… 
Highly Cited
2000
Highly Cited
2000
Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
UNLABELLED A phase I therapy study was conducted to determine the safety, maximum tolerated dose (MTD), pharmacokinetics… 
Highly Cited
2000
Highly Cited
2000
Targeting of a hydrophilic photosensitizer by use of internalizing monoclonal antibodies: A new possibility for use in photodynamic therapy
Coupling of photosensitizers to tumor‐selective monoclonal antibodies ( MAbs ) is an attractive option for improving the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)